These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 33275064)

  • 1. Therapeutic targeting of the IL-13 pathway in skin inflammation.
    Tubau C; Puig L
    Expert Rev Clin Immunol; 2021 Jan; 17(1):15-25. PubMed ID: 33275064
    [No Abstract]   [Full Text] [Related]  

  • 2. IL-13 antagonists in the treatment of atopic dermatitis.
    Tubau C; Puig L
    Immunotherapy; 2021 Mar; 13(4):327-344. PubMed ID: 33430628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of IL-13: A New Pathway for Atopic Dermatitis [Formula: see text].
    Ratnarajah K; Le M; Muntyanu A; Mathieu S; Nigen S; Litvinov IV; Jack CS; Netchiporouk E
    J Cutan Med Surg; 2021; 25(3):315-328. PubMed ID: 33350863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.
    Moyle M; Cevikbas F; Harden JL; Guttman-Yassky E
    Exp Dermatol; 2019 Jul; 28(7):756-768. PubMed ID: 30825336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of interleukin-13 signalling improves skin barrier function and biology in patients with moderate-to-severe atopic dermatitis.
    Sander N; Stölzl D; Fonfara M; Hartmann J; Harder I; Suhrkamp I; Jakaša I; van den Bogaard E; van Vlijmen-Willems I; Szymczak S; Rodriguez E; Gerdes S; Weidinger S
    Br J Dermatol; 2024 Aug; 191(3):344-350. PubMed ID: 38531691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.
    Guttman-Yassky E; Kabashima K; Staumont-Salle D; Nahm WK; Pauser S; Da Rosa JC; Martel BC; Madsen DE; Røpke M; Arlert P; Steffensen L; Blauvelt A; Reich K
    Allergy; 2024 Jun; 79(6):1560-1572. PubMed ID: 38563683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological agents targeting interleukin-13 for atopic dermatitis.
    Chiricozzi A; Gori N; Maurelli M; Gisondi P; Caldarola G; De Simone C; Peris K; Girolomoni G
    Expert Opin Biol Ther; 2022 May; 22(5):651-659. PubMed ID: 35081849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asthma and Atopic Dermatitis: A Review of Targeted Inhibition of Interleukin-4 and Interleukin-13 As Therapy for Atopic Disease.
    Buzney CD; Gottlieb AB; Rosmarin D
    J Drugs Dermatol; 2016 Feb; 15(2):165-71. PubMed ID: 26885783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis.
    Pescitelli L; Rosi E; Ricceri F; Pimpinelli N; Prignano F
    Curr Pharm Biotechnol; 2021; 22(1):73-84. PubMed ID: 32525769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tralokinumab for the Treatment of Atopic Dermatitis.
    Freitas E; Guttman-Yassky E; Torres T
    Am J Clin Dermatol; 2021 Sep; 22(5):625-638. PubMed ID: 34155602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
    Kraft M; Worm M
    Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective IL-13 inhibitors for the treatment of atopic dermatitis.
    Gonçalves F; Freitas E; Torres T
    Drugs Context; 2021; 10():. PubMed ID: 33889195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab for the treatment of adolescents with atopic dermatitis.
    Senner S; Seegräber M; Frey S; Kendziora B; Eicher L; Wollenberg A
    Expert Rev Clin Immunol; 2020 Jul; 16(7):641-650. PubMed ID: 32720530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologics for Atopic Dermatitis.
    Boguniewicz M
    Immunol Allergy Clin North Am; 2020 Nov; 40(4):593-607. PubMed ID: 33012322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug evaluation review: dupilumab in atopic dermatitis.
    Hamilton JD; Ungar B; Guttman-Yassky E
    Immunotherapy; 2015; 7(10):1043-58. PubMed ID: 26598956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab: A review of its use in the treatment of atopic dermatitis.
    Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab for atopic dermatitis: evidence to date.
    Rodrigues MA; Nogueira M; Torres T
    G Ital Dermatol Venereol; 2019 Dec; 154(6):696-713. PubMed ID: 31210470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab for Moderate-to-Severe Atopic Dermatitis.
    Vangipuram R; Tyring SK
    Skin Therapy Lett; 2017 Nov; 22(6):1-4. PubMed ID: 29091379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.
    Yang N; Chen Z; Zhang X; Shi Y
    BioDrugs; 2021 Jul; 35(4):401-415. PubMed ID: 34213742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-4 and IL-13 Inhibition in Atopic Dermatitis.
    Matsunaga MC; Yamauchi PS
    J Drugs Dermatol; 2016 Aug; 15(8):925-9. PubMed ID: 27537991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.